Cystatin C vs Creatinine eGFR in Advanced CKD: an analysis of the STOP-ACEi Trial

  • Published on 09/04/2024
  •  Reading time: 4 min.

Sebastian Spencer, 1,2,3, Robert Desborough, 2,3, Samir Mehta, 4, Natalie Ives, 4, Sunil Bhandari 2,3

1 University of Hull
2 Hull York Medical School
3 Hull University Teaching Hospitals NHS Trust
4 Birmingham Clinical Trials Unit, University of Birmingham

Correspondence to: Sebastian Spencer; E-mail: sebastian.spencer2@nhs.net

Abstract

Background and hypothesis In this secondary analysis of the STOP-ACEi trial, we explored the impact of discontinuing or continuing renin angiotensin system inhibitor therapy in people with advanced chronic kidney disease on cystatin C estimated glomerular filtration rate.
Methods Cystatin C eGFR were calculated at baseline, 12-, 24- and 36-months using CKD-EPI Cystatin 2012, EKFC and CKD-EPI Combined 2021 equations. We excluded samples obtained after the...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Nephrology

Receive our newsletter to stay up to date with the latest news in Nephrology

More articles

From peer-reviewed journals in Nephrology